• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Daiichi Sankyo Ltd ADR (OP: DSNKY )

    35.62 +0.39 (+1.11%)
    Streaming Delayed Price Updated: 3:59 PM EDT, Jul 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 33,187
    Open 36.70
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 35.23
    Today's Range 35.58 - 36.70
    52wk Range 23.72 - 37.72
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
    The FDA issued a Complete Response Letter for Daiichi Sankyo and Merck's BLA for patritumab deruxtecan targeting EGFR-mutated NSCLC due to third-party manufacturing facility inspection findings. The... 
    Via Benzinga
    Exposures Product Safety
    Why Is AstraZeneca Stock Trading Lower On Tuesday?
    AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patients. While the overall trial did not reach statistical significance. 
    Via Benzinga

    Performance

    YTD
    +31.49%
    +31.49%
    1 Month
    -0.86%
    -0.86%
    3 Month
    +14.35%
    +14.35%
    6 Month
    +27.85%
    +27.85%
    1 Year
    +26.36%
    +26.36%

    More News

    Read More
    DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q3 2023
    Via InvestorPlace
    Double Good News For AstraZeneca's Breast Cancer Drugs
    Via Benzinga
    AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
    Via Benzinga
    Exposures Product Safety
    Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact
    Via Benzinga
    Daiichi Sankyo Seeks Approval In Japan For Its mRNA-Based COVID-19 Vaccine
    Via Benzinga
    This Cancer Focused Stock Has 60% Potential Upside, Bullish Analyst Says
    Via Benzinga
    What's Going On With Pfizer Stock Today?
    Via Benzinga
    Why Pharmaceutical Company Esperion Therapeutics Shares Are Diving Today
    Via Benzinga
    Japan Emerges As Promising 2024 Investment Destination: 3 Stocks To Consider
    Via Benzinga
    Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?
    Via The Motley Fool
    Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
    Via Benzinga
    AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials
    Via Benzinga
    FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt
    Via Benzinga
    Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
    Via Benzinga
    AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
    Via Benzinga
    Japanese Pharma Company Sponsors Australian Start Up In Development Of Non-Hallucinogenic Medicines
    Via Benzinga
    AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
    Via Benzinga
    Is Gilead Sciences a Good Stock to Buy Now?
    Via The Motley Fool
    AstraZeneca’s Next “Wonder Drug”
    Via Talk Markets
    AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
    Via Benzinga
    AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients
    Via Benzinga
    European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs
    Via Benzinga
    With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.